Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Resveravine is a standardized natural extract derived from the stems of the grapevine (*Vitis vinifera L.*), developed by the French company Nexira. It is characterized by a high concentration of oligostilbenes, specifically containing 20% active components including trans-resveratrol and ε-viniferin. As a nutraceutical ingredient, it functions primarily as an antioxidant and anti-aging compound by targeting the SIRT-1 (sirtuin-1) gene, which plays a critical role in longevity and metabolic regulation. Resveravine is marketed for use in dietary supplements to support cardiovascular health, provide anti-inflammatory effects, and promote healthy aging. It is chemically distinct from simple resveratrol extracts due to its specific profile of grapevine-derived stilbenoids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on resveravine.